Ticker

PFE

LLY

JNJ

ABBV

Headquarter

New York ,NY

Indianapolis ,IN

New Brunswick ,NJ

North Chicago ,IL

CEO

Dr. Albert Bourla D.V.M., Ph.D.

Mr. David A. Ricks

Mr. Joaquin Duato

Mr. Robert A. Michael

Industry

Drug Manufacturers - General

Stock Price

Market Cap

$150.69B

$742.35B

$347.15B

$320.24B

Employees

Years

2021
2022
2023

2022
2023

2022
2023

2022
2023

Employees

79.00K
83.00K
88.00K

39.00K
43.00K

141.70K
152.70K

50.00K
50.00K

Y/Y

0.64%

5.06%

6.02%

11.43%

10.26%

5.35%

7.76%

Income Statement

Revenue

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Revenue

$81.29B
$100.33B
$58.50B

$28.54B
$34.12B

$78.74B
$79.99B
$85.16B

$58.05B
$54.32B

Y/Y

93.97%

23.43%

41.7%

0.79%

19.56%

4.65%

1.59%

6.46%

3.3%

6.44%

Revenue by Products / Services

Revenue by Geography

Research and Development

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Research and Development

$13.83B
$11.43B
$10.68B

$7.19B
$9.31B

$14.28B
$14.14B
$15.05B

$6.51B
$8.45B

Y/Y

47.04%

17.36%

6.55%

2.35%

29.52%

15.7%

0.99%

6.46%

8.1%

29.85%

Operating Income

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Operating Income

$24.83B
$40.03B
$3.36B

$7.13B
$10.33B

$20.47B
$23.19B
$23.41B

$18.12B
$12.76B

Y/Y

133.61%

61.2%

91.61%

12.12%

44.87%

20.8%

13.3%

0.93%

1.08%

29.59%

Tax Rate (%)

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Tax Rate (%)

8.00%
10.00%
-105.00%

8.00%
20.00%

7.00%
15.00%
12.00%

12.00%
22.00%

Y/Y

19.81%

25.72%

1199.06%

11.48%

143.03%

33.58%

115.04%

25.32%

9.2%

81.92%

Net Income

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Net Income

$21.98B
$31.37B
$2.12B

$6.24B
$5.24B

$20.88B
$17.94B
$35.15B

$11.84B
$4.86B

Y/Y

213.09%

42.74%

93.25%

11.88%

16.08%

41.89%

14.07%

95.94%

2.55%

58.91%

Assets & Liabilities | Cash Flow

Total Assets

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Total Assets

$181.48B
$197.21B
$226.50B

$49.49B
$64.01B

$182.02B
$187.38B
$167.56B

$138.81B
$134.71B

Y/Y

17.67%

8.67%

14.86%

1.4%

29.33%

4.07%

2.94%

10.58%

5.27%

2.95%

Total Liabilities

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Total Liabilities

$104.01B
$101.29B
$137.21B

$38.71B
$53.14B

$108.00B
$110.57B
$98.78B

$121.52B
$124.31B

Y/Y

14.61%

2.62%

35.47%

2.36%

37.27%

3.24%

2.39%

10.66%

7.3%

2.3%

Capital Expenditures (Capex)

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Capital Expenditures (Capex)

-$2.71B
-$3.24B
-$3.91B

-$2.48B
-$7.39B

-$3.65B
-$4.01B
-$4.54B

-$695.00M
-$777.00M

Y/Y

2.87%

19.37%

20.74%

32.61%

197.59%

9.11%

9.78%

13.32%

11.69%

11.8%

Profitability

Operating Income Margin (%)

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Operating Income Margin (%)

30.55%
39.90%
5.74%

24.97%
30.26%

26.00%
28.99%
27.49%

31.21%
23.49%

Y/Y

20.42%

30.61%

85.61%

11.22%

21.19%

26.71%

11.5%

5.17%

2.13%

24.74%

Net Income Margin (%)

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Net Income Margin (%)

27.04%
31.27%
3.62%

21.88%
15.36%

26.52%
22.43%
41.28%

20.39%
8.95%

Y/Y

61.43%

15.64%

88.42%

11.01%

29.8%

48.82%

15.42%

84.04%

0.73%

56.11%

EBITDA

2020	13168000000.00
2021	30793000000.00
2022	41031000000.00
2023	9557000000.00

2021	8042900000.00
2022	8660500000.00
2023	8567800000.00

2021	27498000000.00
2022	30925000000.00
2023	27170000000.00
2023	23725000000.00

2021	28280000000.00
2022	31424000000.00
2023	17308000000.00

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

EBITDA

$30.79B
$41.03B
$9.56B

$8.66B
$8.57B

$30.93B
$27.17B
$23.73B

$31.42B
$17.31B

Y/Y

133.85%

33.25%

76.71%

7.68%

1.07%

12.46%

12.14%

12.68%

11.12%

44.92%

Free Cash Flow (FCF)

2020	11612000000.00
2021	29869000000.00
2022	26031000000.00
2023	4793000000.00

2021	5387500000.00
2022	4600400000.00
2023	-3152000000.00

2021	20189000000.00
2022	19758000000.00
2023	17185000000.00
2023	18248000000.00

2021	21990000000.00
2022	24248000000.00
2023	22062000000.00

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Free Cash Flow (FCF)

$29.87B
$26.03B
$4.79B

$4.60B
-$3.15B

$19.76B
$17.19B
$18.25B

$24.25B
$22.06B

Y/Y

157.23%

12.85%

81.59%

14.61%

168.52%

2.13%

13.02%

6.19%

10.27%

9.02%

Ratios

Return on Equity (ROE)

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Return on Equity (ROE)

28.47%
32.79%
2.38%

58.64%
48.65%

28.20%
23.36%
51.11%

68.60%
46.94%

Y/Y

156.49%

15.17%

92.74%

5.66%

17.04%

21.29%

17.16%

118.79%

8.42%

31.57%

Return on Assets (ROA)

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Return on Assets (ROA)

12.11%
15.91%
0.94%

12.62%
8.19%

11.47%
9.57%
20.98%

8.53%
3.61%

Y/Y

166.15%

31.38%

94.09%

10.31%

35.1%

36.39%

16.56%

119.23%

8.25%

57.68%

Debt to Equity

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Debt to Equity

47.92%
36.45%
80.76%

152.48%
234.18%

45.60%
51.61%
42.65%

366.70%
573.21%

Y/Y

23.92%

23.94%

121.56%

18.91%

53.58%

18.18%

13.18%

17.36%

26.32%

56.32%

Valuation

Enterprise Value

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Enterprise value

$365.79B
$321.81B
$230.45B

$344.06B
$546.67B

$470.24B
$488.44B
$404.57B

$340.28B
$320.56B

Y/Y

51.8%

12.02%

28.39%

30.53%

58.89%

8.53%

3.87%

17.17%

10.99%

5.8%

Enterprise value to Revenue

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Enterprise value to Revenue

4.50
3.21
3.94

12.05
16.02

5.97
6.11
4.75

5.86
5.90

Y/Y

21.74%

28.72%

22.83%

29.51%

32.89%

13.83%

2.25%

22.2%

7.44%

0.68%

Enterprise value to EBITDA

Years

2021
2022
2023

2022
2023

2022
2023
2023

2022
2023

Enterprise value to EBITDA

11.88
7.84
24.11

39.73
63.81

15.21
17.98
17.05

10.83
18.52

Y/Y

35.09%

33.98%

207.45%

21.22%

60.61%

3.5%

18.23%

5.14%

0.12%

71.03%

Pfizer Competitors & Alternatives

Income Statement

Assets & Liabilities | Cash Flow

Profitability

Ratios

Valuation

Facebook

Instagram

Twitter

About Us

Blog

FAQ

Glossary

Privacy Policy

Contact us

Submit Feedback

Advertise with Us

Pfizer Competitors & Alternatives

Income Statement

Assets & Liabilities | Cash Flow

Profitability

Ratios

Valuation

Related company

Submit feedback to Bullfincher